WHAT IS HT-002?
HT-002 is a novel peptide therapeutic targeted for the treatment of illness associated with SARS-CoV-2 infection (COVID-19 disease). The peptide is also under evaluation for potential prophylactic therapeutic benefits as well.
DEVELOPMENT STATUS
HT-002 is at the preclinical stage of development.
Upcoming Milestones:
EXTERNAL RESOURCES
INVESTOR RELATIONS
Hoth Therapeutics seeks to enhance shareholder value not only through business performance and practices, but also through responsible and effective communication with its shareholders.